Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Costs and expenses | ||
| Cost of revenues(a) | 23,391 | 15,763 |
| Research and development | 39,438 | 26,927 |
| Selling, general and administrative | 125,173 | 89,944 |
| Amortization of intangible assets | 25,644 | 19,786 |
| Contingent consideration loss | 2,391 | 7,660 |
| Total costs and expenses | 216,037 | 160,080 |
| Operating loss | (8,332) | (10,256) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's SG&A?
- Supernus Pharmaceuticals (SUPN) reported SG&A of $125.17M in Q1 2026.
- How has Supernus Pharmaceuticals's SG&A changed year-over-year?
- Supernus Pharmaceuticals's SG&A increased by 39.2% year-over-year, from $89.94M to $125.17M.
- What is the long-term trend for Supernus Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's SG&A has grown at a 12.3% compound annual growth rate (CAGR), from $304.76M to $485.56M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Supernus Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude